Abstract
Purpose :
To evaluate the factors associated with additional intravitreal bevacizumab injection against diabetic macular edema(DME) including systemic factors.
Methods :
Medical records for 114 eyes of 99 patients with diabetic macular edema were retrospectively reviewed. All patients received intravitreal bevacizumab injection of 1.25mg (0.05cc) at baseline. The injection was repeated when DME aggravated. We analyzed the correlation between the number of additional injections for 12 months and various factors as follows; (1) Systemic factors: Hypertension, HbA1c, eGFR, Duration of diabetes, (2) Ocular factors: history of panretinal photocoagulation (PRP), Central macular thickness (CMT) and macular volume (MV), and DME OCT types; diffuse retinal thickening (DRT), cystoid macular edema (CME), serous retinal detachment (SRD).
Results :
DME OCT type, CMT and MV at 1month after baseline were significantly related to the number of additional injections (P < 0.05). The mean number of injections over 12 months was different among the DME OCT Types (DRT = 2.67, CME = 4.01, SRD = 4.10; P=0.049). CMT and MV at 1month after baseline had positive correlation with more additional bevacizumab injection (CMT, Exp(B) = 1.027 (95% CI = 1.007-1.048, P=0.008); MV, Exp(B) = 2.013 (95% CI = 1.079-3.574, P=0.028). On the other hand, other factors were not correlated with the number of the injections (P > 0.05).
Conclusions :
In terms of OCT types, patients with DRT maintained an anatomical improvement with fewer additional intravitreal bevacizumab injections over 12 months. The greater the CMT and MV values at 1month after baseline, the more injections were required.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.